News by subject: TRI

Proprietary E3 ligase platform to enable protein stabilisation "at source", thereby restoring the body's sophisticated natural disease suppression processes Platform scales the assessment of E3 ligase targets while addressing the historic challenges...

TaiGen Biotechnology Company, Limited ("TaiGen") announces today that the business partner, Joincare Pharmaceutical, has completed the unblinding of influenza antiviral TG-1000 phase III study. Preliminary data shows that the median time to...

Biohaven Ltd. , a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience and oncology, today announced that it has commenced an...

Genscience LLC, a company applying genetic evidence and proprietary platforms for drug discovery and development and an affiliate of Deerfield Management Company ("Deerfield"), a healthcare investment firm, today announced a new study that shows...

Aspen Neuroscience, Inc. announced that the first patient has been dosed in the ASPIRO trial, a Phase 1/2a open label clinical trial to assess safety and tolerability of ANPD001, an autologous, dopaminergic neuron cell replacement therapy for...

Asieris Pharmaceuticals today released its 2023 Annual Report, revealing impressive outcomes achieved through its specialty pharma strategy, which has facilitated rapid progress in clinical development, early research, and commercialization. Asieris...

SalioGen Therapeutics, a biotechnology company developing next-generation genetic medicines based on its novel Gene Codingtm technology, today...

The choices made in clinical trial setup ? from patient recruitment strategies to data collection methods ? directly impact the success and...

New data demonstrates no impact of NRX-101 on gut or vaginal flora ? considered primary causes of pseudomembranous colitis due to C difficile and vaginal yeast infectionsNRX-101 previously demonstrated potent activity against resistant urinary...

In this free webinar, learn from real-world trials to understand the practical implications, benefits and challenges of eSource integration. Attendees will master the complexities of navigating site readiness by effectively engaging stakeholders and...

NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced dosing of the first patient in the single...

Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced that David J. Bearss, Ph.D., President and CEO of Halia Therapeutics, will present...

Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced the presentation of two posters...

Allegheny Health Network's (AHN) Allegheny General Hospital (AGH) was the top U.S. enrollment site for a landmark international clinical trial comparing the performance and durability of self-expanding and balloon-expandable transcatheter aortic...

BioLineRx Ltd. , a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced a poster presentation on apheresis center efficiency and CXCR4 antagonists including APHEXDA...

Eli Lilly and Company today...

A new clinical study shows DigeSEB Sporttm, a potent sports nutrition ingredient offered by Specialty Enzymes & Probiotics, promotes protein digestion and nutrient bioavailability, a healthy gut microbiome, and the production of postbiotics, such as...

SimonMed Imaging ("SimonMed"), one of the largest outpatient medical imaging providers and radiology practices in the United States, announces the continuation of its partnership with SyntheticMR for research as well as the upcoming expansion of...

Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (?3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis of the ALITHIOS open-label extension study1 Similar...

Amgen today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American...

Community research provider EmVenio Research and Prime Healthcare, an award-winning national health system, today announce their partnership to launch the EmVenio Research Center at Prime Healthcare. The partnership allows EmVenio to conduct research...

New research in the April 2024 issue of JNCCN?Journal of the National Comprehensive Cancer Network showcases the feasibility of...

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, presented the preclinical research findings of three potential novel drug candidates in poster format at the American Association for Cancer Research...

BOSTON, April 16, 2024 /PRNewswire/ ? Researchers from Analysis Group, a global leader in health economics and outcomes research (HEOR), have coauthored the first large-scale study that revealed racial disparities in treatment, survival, and access...

EV?Q Nano, a nanoscience company that engineers novel nanoparticles for the life, materials, and textile science industries, today announced that the American Chemical Society journal, ACS Omega, published a peer-reviewed study characterizing and...

Integral Molecular, a leader in providing safe research reagents for virology, announces the launch of its Virus Neutralization Assay Services enabling researchers to rapidly obtain high-quality data to advance their vaccines and...

Evergreen Theragnostics, Inc., a clinical-stage radiopharmaceutical company, today announced the successful completion of a $26M capital raise supported both by existing shareholders and new institutional investors, Petrichor and LIFTT. The financing...

An upcoming segment of Advancements with Ted Danson will focus on developments in research, testing, and treatments for a wide range of cancers and chronic terminal illnesses. With a look at Magnus Diagnostics Laboratories, Inc. (Magnus), audiences...

Beckman Coulter Diagnostics, a leader in clinical diagnostics, announced today, ahead of the congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global), that it has extended the menu of DxI 9000 Immunoassay...

LongBio Pharma (Suzhou) Co., Ltd. (referred to as "LongBio"), a leading biotech company dedicated to developing innovative protein treatments for nephrology, allergy, respiratory, hematology, ophthalmology, and other autoimmune and rare diseases,...

APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN1IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney...

Norgine B.V. today announced its first marketing authorisation application submissions on 10 April 2024, seeking approval for eflornithine in high-risk neuroblastoma (HRNB), via Project Orbis in Australia, Switzerland and the United Kingdom. This...

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of one abstract in amyotrophic lateral sclerosis (ALS) at the Academy of Managed Care Pharmacy (AMCP) 2024 Annual Meeting, being held in New Orleans, La., Apr. 15-18,...

Research Solutions , a trusted partner providing cloud-based workflow solutions to accelerate research for R&D-driven organizations, today launches their new Clinical Trial Landscape software solution, making clinical trial information more...

Data presentation at highly influential American Society of Breast Surgeons ("ASBrS") Annual Meeting by Dr. Richard Fine wins Scientific Impact Award as voted by breast surgeons President-Elect of the ASBrS, Dr. Michael Berry, presents data and...

Medivir AB (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its partner Vetbiolix, a veterinary biotechnology company based in France,...

Actinogen Medical Limited announces that the first patient has been randomized and treated in the XanaMIA phase 2b clinical trial in patients with...

Professor Julia Scarisbrick of University of Birmingham on Friday, April 12, 2024, presented interim findings from the Kyowa Kirin, Inc. (Kyowa Kirin, TSE: 4151)-sponsored study, "Real-World Observational Study of Mogamulizumab in Adult Patients with...

Fluence, a global leader in education, training, and certification for practitioners of psychedelic medicine, and Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to pushing the boundaries of...

Experts from NYU Langone's Department of Neurology present their latest clinical findings and research discoveries at the American Academy of Neurology (AAN) 2024 Annual Meeting, April 13 to 18, in Denver....

Biohaven's first-in-class Molecular Degrader of Extracellular Proteins (MoDEtm) technology targeting IgG removal, BHV-1300, was selected for an oral presentation at AAN highlighting its novel mechanism of action and the latest preclinical data...

Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company based in Japan, will announce findings from an updated systematic literature review (SLR) and meta-analysis comparing the...

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced seven presentations will be shared at the American Academy of Neurology (AAN) 2024 Annual Meeting being held in Denver, Colo.,...

TransThera Sciences, a clinical-stage biopharmaceutical company focused on inventing differentiated drugs for global patients, announced the poster presentation at the 2024 American Association for Cancer Research (AACR) to discuss the latest...

NeuroSense Therapeutics Ltd. ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, announces lead author Merit Cudkowicz, Chair of Neurology at Massachusetts General Hospital, and Julieanne Dorn Professor of...

Eisai Inc. announced today the Company will present findings from its robust neurology portfolio, including data from the Phase 3 Clarity AD trial for LEQEMBI® (lecanemab-irmb), Eisai's anti-amyloid beta (A?) protofibril* antibody for the treatment...

-     Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine-     Seventy percent of subjects achieved ?50% reduction in monthly...

Diverse and patient-focused data set comprises 17 abstracts including one oral presentationFeatures new data analyses for UCB's generalized myasthenia gravis (gMG) treatments, including post hoc and open-label extension results from the pivotal Phase...

Diamyd Medical's precision medicine Phase 3 trial for Type 1 Diabetes, DIAGNODE-3, has enrolled 100 patients. To date, no serious adverse events have been reported, and no patients have discontinued the trial. "This is an important milestone in our...

Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the recent release of V-Wave's RELIEVE-HF trial data supporting the evidence base around atrial shunt therapy, which is currently under study in the...